But pioneering 900S system process too costlyToshiba's helical CT technology is evolving at a rapid pace. Followingintroduction of the premium Xpress/SX system late last year (SCAN11/17/93), the vendor will add a mid-tier price point to its
Toshiba's helical CT technology is evolving at a rapid pace. Followingintroduction of the premium Xpress/SX system late last year (SCAN11/17/93), the vendor will add a mid-tier price point to its helicalline in 1994 with Xvision. Toshiba America Medical Systems willalso phase out sales of its pioneering fourth-generation, slip-ring-based900S system, introduced in 1986.
Japanese sales of Toshiba's compact Xvision scanner are slatedto begin in July. A 510(k) application to the Food and Drug Administrationfor U.S. market clearance should be filed this year, said DavidEaton, TAMS CT product manager.
Xvision is about half the size and nearly a third lighter thanstandard helical scanners. It uses the same console as Xpressand the non-helical Xpeed scanner but packs a redesigned gantry.Xvision could expand CT applications and market opportunitiesfor Toshiba. For instance, it might allow use of volumetric CTimaging in the operating room to guide surgery.
With the competitive market determining CT system price levels,the high cost of producing 900S has made the scanner less profitablefor the vendor. After selling its last two units in U.S. inventoryduring 1994, TAMS plans no further orders of 900S from Japan.The system will continue to be sold internationally.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.